TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06531226

Intervention type: OTHER
Intervention: Fill in personality questionnaires
Description: For patients who need to undergo colonoscopy, we invite them to fill out a personality survey questionnaire after obtaining their informed consent. The questionnaire contains 60 survey questions, which cover the five dimensions of the Big Five personality traits. Each question has five options, corresponding to the five states of very disagree to very agree. The questionnaire was developed based on the Chinese population and has four norms applicable to different age groups to ensure the reliability of the questionnaire.

Intervention type: OTHER
Intervention: Fill in personality questionnaires
Description: For patients who need to undergo colonoscopy, we invite them to fill out a personality survey questionnaire after obtaining their informed consent. The questionnaire contains 60 survey questions, which cover the five dimensions of the Big Five personality traits. Each question has five options, corresponding to the five states of very disagree to very agree. The questionnaire was developed based on the Chinese population and has four norms applicable to different age groups to ensure the reliability of the questionnaire.
Study: NCT05005221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated text messages
Description: Automated text messages will be used to facilitate blood sample collection at home for therapeutic drug monitoring of tacrolimus and mycophenolate. Participants will collect dried blood samples on 4 occasions. Two days in the clinical with simultaneous venipuncture (one sample) and two days at home with 4 samples collected at specified time points over 8 hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Automated text messages
Description: Automated text messages will be used to facilitate blood sample collection at home for therapeutic drug monitoring of tacrolimus and mycophenolate. Participants will collect dried blood samples on 4 occasions. Two days in the clinical with simultaneous venipuncture (one sample) and two days at home with 4 samples collected at specified time points over 8 hours.
Study: NCT04831905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro-wave ablation
Description: Micro-wave ablation
Study: NCT06103344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-7-8 Breathing Exercise Training
Description: Participants in the intervention group will be taught 4-7-8 breathing exercises collectively, and the training will be repeated on specified days (twice a week for a total of 4 weeks). During the training, it will be checked whether each participant in the intervention group can perform the breathing exercise correctly and feedback will be given. Participants who fail to implement the exercise will be excluded from the study. 4-7-8 breathing exercise training, prepared in accordance with the literature, will be given by the assistant researcher who has training and certification in breathing exercises. Training will be planned in an empty classroom, for approximately 20 minutes and at the students' end time. Thus, educational activities in the institution will not be disrupted.
Study: NCT05585073

Intervention type: OTHER
Intervention: Whether lymph node dissection is qualified or not
Description: Klass-02-QC LND scale and general error score tool were used to quantitatively evaluate the intraoperative performance of D2 LND

Intervention type: OTHER
Intervention: Whether lymph node dissection is qualified or not
Description: Klass-02-QC LND scale and general error score tool were used to quantitatively evaluate the intraoperative performance of D2 LND
Study: NCT04417114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Statin
Study: NCT04374279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide 150 Mg Oral Tablet
Description: Bicalutamide 150 mg by mouth daily for 7 days
Study: NCT05409768

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short axis out of plane
Description: A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance short axis visualisation out of plane approaches.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anteroposterior short axis in plane
Description: A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance anteroposterior short axis visualisation in plane approaches.
Study: NCT05308615

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rhea® Health Tone
Description: Rhea® Health Tone

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rhea® Health Tone
Description: Rhea® Health Tone
Study: NCT05583838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: initial therapy: rhTPO s.c, 300 or 600U/kg daily based on baseline platelet count; maintenance therapy: rhTPO s.c, 300 \~ 600U/kg every other day depends on platelet count.
Study: NCT06442657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrocellular dressing
Description: Application of hydrocellular dressings to at-risk areas prior to prone positioning. Assessment of pressure sores and their stage after prone positioning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocolloids dressing
Description: Application of hydrocolloids dressings to at-risk areas prior to prone positioning.
Study: NCT05583838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag
Description: initial therapy: Eltrombopag oral, 25 or 50mg daily based on baseline platelet count; maintenance therapy: Eltrombopag oral, 25 \~ 75mg daily or every other day depends on platelet count.
Study: NCT05592392

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Synchronized Diaphragmatic Stimulation
Description: Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synchronized Diaphragmatic Stimulation
Description: Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.
Study: NCT06003777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522
Description: PF-06954522 will be administered as oral suspensions as escalating single doses to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522
Description: PF-06954522 will be administered as oral suspensions as escalating single doses to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522
Description: PF-06954522 will be administered as oral suspensions as escalating single doses to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as oral suspensions as escalating single doses to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as oral suspensions as escalating single doses to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as oral suspensions as escalating single doses to be determined.
Study: NCT05836272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine Bitartrate
Description: The NE will be prepared as follows: 4 mg mixed with 250 ml of 5% glucose resulting in a final norepinephrine concentration of 0.016 mg/ml. For the control group placebo: 250 ml of 5% glucose will be prepared.~Both drugs will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour, adjusted according to body weight to obtain norepinephrine at 0.05 microgram/kg/min (ie 0.128 to 0.24 mg per hour) in continuous infusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the control group placebo: 250 ml of 5% glucose will be prepared and will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour.
Study: NCT05144776

Intervention type: DIAGNOSTIC_TEST
Intervention: GeneXpert HBV DNA Viral Load Assay
Description: The Xpert venous blood HBV DNA viral load assay will be adapted to operate using fingerstick capillary blood samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dried Blood Spot HBV DNA test
Description: HBV DNA viral load will be measured from a fingerstick capillary dried blood spot sample using a gold standard HBV DNA viral load assay
Study: NCT06118424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: deepfake video
Description: The combination of the words deep and fake is called deepfake in the literature as deep learning. Deepfakes, which have recently become more widely known as a result of the shocking images and sound recordings of many people, from politicians to famous movie stars, are generally hyperrealistic videos in which people's faces and voices are used by other faces and voices without permission and manipulated digitally. Deepfakes rely on neural networks that analyze large data samples to learn to mimic a person's facial expressions, mannerisms, voice and tone. The process involves feeding a deep learning algorithm to exchange images of two people or faces.
Study: NCT05669040

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological education
Description: Inform the patient of the medication that is being taken and how it has to be taken; What is it for and the side effects and/or adverse reactions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological education
Description: Inform the patient of the medication that is being taken and how it has to be taken; What is it for and the side effects and/or adverse reactions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training in the use of MyPlan Aplication
Description: Review of the use of the aplication

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training in the use of MyPlan Aplication
Description: Review of the use of the aplication

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Experience
Description: * How do you feel?~* Sad feelings and frustration.~* Achievements day by day, think positive.~* Importance of interpersonal relationships.~* Explain activities to relax the mind

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Experience
Description: * How do you feel?~* Sad feelings and frustration.~* Achievements day by day, think positive.~* Importance of interpersonal relationships.~* Explain activities to relax the mind
Study: NCT05554276

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy
Description: All patients received three cycles of 21 days each, with chemotherapy on day 1 (nab-paclitaxel 150 mg/m2 plus cisplatin 75 mg/m2) and camrelizumab 200 mg, followed by radical radiotherapy.
Study: NCT04978116

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Chest X-Ray (CXR)
Description: The 3 following imagings will be performed in the emergency room: chest X-Ray (CXR), low-dose CT scan (LDCT) and lung ultrasonography (LUS) will be performed for all included patients, but only one will be available to the clinician in charge of the patient according to the allocation arm.~The blinding will be maintained during the first 5 days, and hence will not influence the diagnosis and the treatment of the patient.~The clinician in charge will be asked to assess on a 3-level Likert scale the probability of pneumonia (high, intermediate, low level) while considering all available clinical and biological data, plus the imaging modality according to the randomization arm.
Study: NCT02683018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Smoked Cannabis High CBD/low THC
Description: Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (15.76% CBD; 3.11% THC) over the course of a 2-3 hour session.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Smoked Placebo Cannabis Low CBD/low THC
Description: Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (0.01% THC; 0.00% CBD) over the course of a 2-3 hour session.
Study: NCT04978116

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Chest X-Ray (CXR)
Description: The 3 following imagings will be performed in the emergency room: chest X-Ray (CXR), low-dose CT scan (LDCT) and lung ultrasonography (LUS) will be performed for all included patients, but only one will be available to the clinician in charge of the patient according to the allocation arm.~The blinding will be maintained during the first 5 days, and hence will not influence the diagnosis and the treatment of the patient.~The clinician in charge will be asked to assess on a 3-level Likert scale the probability of pneumonia (high, intermediate, low level) while considering all available clinical and biological data, plus the imaging modality according to the randomization arm.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Chest X-Ray (CXR)
Description: The 3 following imagings will be performed in the emergency room: chest X-Ray (CXR), low-dose CT scan (LDCT) and lung ultrasonography (LUS) will be performed for all included patients, but only one will be available to the clinician in charge of the patient according to the allocation arm.~The blinding will be maintained during the first 5 days, and hence will not influence the diagnosis and the treatment of the patient.~The clinician in charge will be asked to assess on a 3-level Likert scale the probability of pneumonia (high, intermediate, low level) while considering all available clinical and biological data, plus the imaging modality according to the randomization arm.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-dose CT scan (LDCT)
Description: See above in CXR paragraph

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-dose CT scan (LDCT)
Description: See above in CXR paragraph

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-dose CT scan (LDCT)
Description: See above in CXR paragraph

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography (LUS)
Description: See above in CXR paragraph. LUS will be performed by another clinician than the one in charge of the patient

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography (LUS)
Description: See above in CXR paragraph. LUS will be performed by another clinician than the one in charge of the patient

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography (LUS)
Description: See above in CXR paragraph. LUS will be performed by another clinician than the one in charge of the patient
Study: NCT05633108

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention will be administered.
Study: NCT04700163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C144-LS and C-135-LS
Description: A combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C144-LS and C-135-LS
Description: A combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C144-LS and C-135-LS
Description: A combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C144-LS and C-135-LS
Description: A combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C144-LS and C-135-LS
Description: A combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein
Study: NCT06332287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of Trilaciclib and Pemetrexed
Description: This was a single-arm, exploratory study of the combination of Trilaciclib and Pemetrexed in patients with non-small cell lung cancer with leptomeningeal metastasis. Observed the incidence of chemotherapy-induced myelosuppression, and imaging was performed every six cycles to assess tumor response.
Study: NCT05028049

Intervention type: DRUG
Intervention: Sufentanil injection
Description: Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia

Intervention type: DRUG
Intervention: Sufentanil injection
Description: Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia

Intervention type: DRUG
Intervention: Remifentanil Hydrochloride
Description: Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia

Intervention type: DRUG
Intervention: Remifentanil Hydrochloride
Description: Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia

Intervention type: OTHER
Intervention: plain areas
Description: Patients should be long staying residents in plain areas (altitude level below 1,000 meters above sea level)

Intervention type: OTHER
Intervention: plain areas
Description: Patients should be long staying residents in plain areas (altitude level below 1,000 meters above sea level)
Study: NCT06266910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual training video
Description: The video, designed according to the principles of pencil pushups, features a dynamic standard E and is presented on an autostereoscopic 3D display equipment.
Study: NCT06028828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given Day-5, Day-4, Day-3, Day-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given Day-5

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Given Day-1
Study: NCT06160596

Intervention type: GENETIC
Intervention: Long term survival multimodal analysis
Description: * To describe global signatures (Digital histology, Radiomic, Genomic, Transcriptomic, Proteomic, (Epigenomic) and clinical signature) that are associated with a patient's unexpected survival compared to standard patients across three cohorts of solid tumors with unmet medical needs.~* To describe global signatures in the overall population (pan-cohort).~* To describe clinical, digital pathology, radiomic, genomic, transcriptomic, proteomic and epigenomic signatures associated with patients' unexpected survival compared to standard patients for each cohort and in all cohorts (pan-cohort)

Intervention type: GENETIC
Intervention: Long term survival multimodal analysis
Description: * To describe global signatures (Digital histology, Radiomic, Genomic, Transcriptomic, Proteomic, (Epigenomic) and clinical signature) that are associated with a patient's unexpected survival compared to standard patients across three cohorts of solid tumors with unmet medical needs.~* To describe global signatures in the overall population (pan-cohort).~* To describe clinical, digital pathology, radiomic, genomic, transcriptomic, proteomic and epigenomic signatures associated with patients' unexpected survival compared to standard patients for each cohort and in all cohorts (pan-cohort)

Intervention type: GENETIC
Intervention: Long term survival multimodal analysis
Description: * To describe global signatures (Digital histology, Radiomic, Genomic, Transcriptomic, Proteomic, (Epigenomic) and clinical signature) that are associated with a patient's unexpected survival compared to standard patients across three cohorts of solid tumors with unmet medical needs.~* To describe global signatures in the overall population (pan-cohort).~* To describe clinical, digital pathology, radiomic, genomic, transcriptomic, proteomic and epigenomic signatures associated with patients' unexpected survival compared to standard patients for each cohort and in all cohorts (pan-cohort)
Study: NCT06266910

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Visual training video
Description: The video, designed according to the principles of pencil pushups, features a dynamic standard E and is presented on an autostereoscopic 3D display equipment.
Study: NCT05527600

Intervention type: DIAGNOSTIC_TEST
Intervention: intensity of acute pain evaluation
Description: the facial expression of each patient will be collected from a short video of 10 seconds, follow by with the evaluation of the pain intensity.
Study: NCT04782804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine+PD-1 Antibody（Tislelizumab）as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine+PD-1 Antibody（Tislelizumab）as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Antibody（Tislelizumab）
Description: PD-1 Antibody（Tislelizumab, 200mg） was given q3w iv.